BOK Financial’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $356K | Sell |
2,112
-81
| -4% | -$12K | ﹤0.01% | 614 |
|
|
2026
Q1 | $289K | Buy |
2,193
+27
| +1% | +$3.58K | ﹤0.01% | 632 |
|
|
2025
Q4 | $307K | Sell |
2,166
-434
| -17% | -$62.9K | ﹤0.01% | 631 |
|
|
2025
Q3 | $365K | Sell |
2,600
-13
| -0.5% | -$1.76K | 0.01% | 623 |
|
|
2025
Q2 | $328K | Sell |
2,613
-3,706
| -59% | -$425K | 0.01% | 640 |
|
|
2025
Q1 | $699K | Buy |
6,319
+2,287
| +57% | +$290K | 0.01% | 487 |
|
|
2024
Q4 | $568K | Buy |
4,032
+13
| +0.3% | +$1.61K | 0.01% | 527 |
|
|
2024
Q3 | $450K | Buy |
4,019
+11
| +0.3% | +$1.51K | 0.01% | 590 |
|
|
2024
Q2 | $552K | Sell |
4,008
-23
| -0.6% | -$3.15K | 0.01% | 579 |
|
|
2024
Q1 | $570K | Buy |
4,031
+25
| +0.6% | +$3.41K | 0.01% | 560 |
|
|
2023
Q4 | $528K | Buy |
4,006
+27
| +0.7% | +$3.11K | 0.01% | 549 |
|
|
2023
Q3 | $441K | Sell |
3,979
-459
| -10% | -$48.3K | 0.01% | 556 |
|
|
2023
Q2 | $419K | Sell |
4,438
-252
| -5% | -$24.6K | 0.01% | 573 |
|
|
2023
Q1 | $475K | Sell |
4,690
-367
| -7% | -$38.2K | 0.01% | 571 |
|
|
2022
Q4 | $604K | Buy |
5,057
+264
| +6% | +$30.9K | 0.01% | 636 |
|
|
2022
Q3 | $509K | Sell |
4,793
-76
| -2% | -$7.71K | 0.01% | 661 |
|
|
2022
Q2 | $475K | Buy |
4,869
+71
| +1% | +$6.55K | 0.01% | 683 |
|
|
2022
Q1 | $450K | Buy |
4,798
+157
| +3% | +$13.3K | 0.01% | 754 |
|
|
2021
Q4 | $395K | Sell |
4,641
-851
| -15% | -$78.3K | 0.01% | 761 |
|
|
2021
Q3 | $527K | Buy |
+5,492
| New | +$519K | 0.01% | 718 |
|
|
2021
Q1 | $1.97M | Buy |
20,208
+1,322
| +7% | +$139K | 0.04% | 389 |
|
|
2020
Q4 | $1.81M | Sell |
18,886
-1,041
| -5% | -$101K | 0.03% | 384 |
|
|
2020
Q3 | $1.92M | Buy |
19,927
+978
| +5% | +$113K | 0.04% | 332 |
|
|
2020
Q2 | $2.31M | Sell |
18,949
-994
| -5% | -$110K | 0.05% | 294 |
|
|
2020
Q1 | $1.73M | Buy |
19,943
+2,821
| +16% | +$276K | 0.05% | 311 |
|
|
2019
Q4 | $1.84M | Sell |
17,122
-636
| -4% | -$66.6K | 0.04% | 377 |
|
|
2019
Q3 | $1.6M | Sell |
17,758
-244
| -1% | -$22.8K | 0.04% | 397 |
|
|
2019
Q2 | $1.52M | Buy |
18,002
+12,455
| +225% | +$1.02M | 0.04% | 395 |
|
|
2019
Q1 | $489K | Sell |
5,547
-10,112
| -65% | -$845K | 0.01% | 675 |
|
|
2018
Q4 | $1.12M | Buy |
15,659
+4,410
| +39% | +$423K | 0.03% | 432 |
|
|
2018
Q3 | $1.38M | Buy |
11,249
+4,601
| +69% | +$522K | 0.03% | 440 |
|
|
2018
Q2 | $653K | Buy |
+6,648
| New | +$595K | 0.02% | 597 |
|
Other funds holding NBIX
BOK Financial's NBIX Position: Q2 2026 in Review
BOK Financial reduced its Neurocrine Biosciences (NBIX) stake by 3.7% in Q2 2026, selling an estimated $12K and leaving 2,112 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #614.
BOK Financial first reported a position in NBIX in Q2 2018 and has held it in 32 quarters since. The position peaked at $2.31M in Q2 2020. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- BOK Financial held 2,112 shares of Neurocrine Biosciences worth $356K as of Q2 2026.
- BOK Financial sold 81 Neurocrine Biosciences shares in Q2 2026, an estimated $12K.
- Neurocrine Biosciences made up ﹤0.01% of BOK Financial's portfolio in Q2 2026, its #614 holding.
- BOK Financial first reported a position in Neurocrine Biosciences in Q2 2018 and has held it in 32 quarters since.
- BOK Financial's Neurocrine Biosciences position peaked at $2.31M in Q2 2020.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.